HONG MAK: Open Payments
NPI 1437568383 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$700 in 14 payments from 10 companies in 2025. Trend: 2023 $187 · 2024 $945 · 2025 $700
Food & beverage: $700
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 3 | $340 |
| AstraZeneca Pharmaceuticals LP | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Syndax Pharmaceuticals, Inc. | 2 | $33 |
| Eisai Inc. | 1 | $31 |
| Janssen Biotech, Inc. | 1 | $30 |
| Genmab U.S., Inc. | 1 | $28 |
| Novartis Pharmaceuticals Corporation | 1 | $22 |
| Deciphera Pharmaceuticals Inc. | 1 | $20 |
| SERVIER PHARMACEUTICALS LLC | 1 | $19 |
Products named: IMFINZI, Vemlidy, Livdelzi, NINLARO, REVUFORJ, Lenvima, TECVAYLI, Tivdak.
Industry payments across NY — which companies pay providers there.
